NextFin News - On December 18, 2025, U.S. President Trump signed a transformative executive order directing the Attorney General to reclassify marijuana from a Schedule I to a Schedule III controlled substance. The move, announced during an Oval Office meeting alongside Health and Human Services Secretary Robert F. Kennedy Jr. and a group of military veterans, effectively ends decades of federal policy that treated cannabis as a drug with no medical value and a high potential for abuse. By shifting marijuana into the same category as anabolic steroids and Tylenol with codeine, the administration has signaled a pragmatic pivot toward medical utility and tax normalization for an industry that has long operated in a legal gray zone.
The most immediate and profound impact of the order is the dismantling of Section 280E of the internal revenue code. For years, state-licensed cannabis operators have been barred from deducting standard business expenses—rent, payroll, and marketing—resulting in effective tax rates that often exceeded 70%. According to industry analysts, the removal of this "punitive tax" could inject billions of dollars in liquidity back into the sector overnight. For major multi-state operators, this is not merely a balance sheet adjustment; it is a lifeline that transforms struggling operations into cash-flow-positive enterprises capable of reinvesting in infrastructure and expansion.
While the tax relief is a victory for the balance sheet, the regulatory landscape remains a complex patchwork. U.S. President Trump’s order does not legalize recreational marijuana at the federal level, nor does it automatically permit interstate commerce. Attorney General Pam Bondi has been tasked with overseeing the rulemaking process "in the most expeditious manner," yet the Drug Enforcement Administration must still navigate administrative hearings and public comment periods. This creates a period of high-stakes transition where the federal government acknowledges the medical legitimacy of the plant while maintaining a prohibitionist stance on its broader commercial movement across state lines.
The scientific community has greeted the reclassification as a long-overdue removal of "research handcuffs." Under Schedule I, researchers faced exhaustive bureaucratic hurdles to obtain samples and funding, stifling the development of standardized pharmaceutical products. By moving to Schedule III, the administration aims to foster a more robust clinical environment. Secretary Kennedy emphasized that the order would prioritize "evidence-based medicine," potentially leading to FDA-approved cannabinoid treatments for chronic pain and PTSD, which have been central to the advocacy efforts of the veterans present at the signing.
Investors have responded with cautious optimism, as the reclassification significantly lowers the risk profile for institutional capital. Previously, many major banks and investment funds avoided the sector to circumvent anti-money laundering complications. While the SAFE Banking Act remains the ultimate goal for many in the industry, Schedule III status provides a stronger legal footing for traditional financial institutions to engage with cannabis clients. The shift suggests a future where the "green rush" is replaced by a more disciplined, pharmaceutical-grade industry, though the tension between state-level recreational markets and federal medical standards will likely persist for years.
Explore more exclusive insights at nextfin.ai.
